

ESTTA Tracking number: **ESTTA1410292**
Filing date: **01/23/2025**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Applicants	Bridge Biotherapeutics Inc.
Application serial no.	97411368
Application filing date	05/15/2022
Mark	KYRIX
Date of publication	12/31/2024
Potential opposer's Correspondence information	ELIZABETH K. RUCKI GSK 410 BLACKWELL STREET DURHAM, NC 27701 UNITED STATES Primary email: trademarks@gsk.com 919-353-8081
Docket no.	84322208

First 30 Day Request for Extension of Time to Oppose

Pursuant to 37 C.F.R. Section 2.102, GlaxoSmithKline Biologicals SA, Rue de l'Institut 89, Rixensart, B-1330, BELGIUM, a Soci t  Anonyme, organized under the laws of Belgium, respectfully requests that it be granted a 30-day extension of time to file a notice of opposition against the above-identified mark.

The time within which to file a notice of opposition is set to expire on 01/30/2025. GlaxoSmithKline Biologicals SA respectfully requests that the time period within which to file an opposition be extended until 03/01/2025.

Respectfully submitted,
/Elizabeth K. Rucki/
Elizabeth K. Rucki
trademarks@gsk.com
01/23/2025